Liquid Biopsy Evaluation and Repository Development at Princess Margaret

  • STATUS
    Recruiting
  • End date
    Jul 28, 2022
  • participants needed
    2500
  • sponsor
    University Health Network, Toronto
Updated on 28 January 2021
cancer
cancer diagnosis
cancer treatment
primary cancer
tumor progression
solid tumor
cfdna

Summary

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.

Details
Condition Pulmonary Disease, urinary tract neoplasm, Ovarian disorder, Colorectal Cancer, Multiple Myeloma, Malignant neoplasm of kidney, Lynch Syndrome, Nephropathy, Meningioma, Disorder of uterus NOS, Uterine Cancer, Lymphoma, Cancer, Mutation, leukemia, Breast Cancer, Multiple hamartoma syndrome, Ovarian Cancer, Malignant neoplasm of colon, melanoma, Hereditary Neoplastic Syndrome, Lung Neoplasm, skin cancer, Lymphoproliferative Disorder, Lymphoma, Bronchial Neoplasm, head and neck cancer, Metastatic Melanoma, Non-Hodgkin's Lymphoma, Kidney Disease (Pediatric), Colon Cancer Screening, Cancer/Tumors, Colon cancer; rectal cancer, Ovarian Function, Breast Cancer Diagnosis, Ewing's Family Tumors, BRCA1 Mutation, BRCA2 Mutation, Recurrent Ovarian Cancer, Leukemia (Pediatric), Cancer (Pediatric), Kidney Cancer, Lung Cancer, Colon Cancer, Malignant Melanoma, Kidney Disease, Lung Disease, Neoplasms, Meningiomas, Uterine Disorders, Hereditary Cancer Syndromes, Renal Cancer, Lymphoproliferative disorders, Urologic Cancer, breast carcinoma, primary cancer, primary malignant neoplasm, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, colon carcinoma, leukemias, malignancy, cancers, malignancies, malignant tumor, malignant tumors, cancer, breast, lymphomas, hnpcc, cancer of the head and neck, multiple myeloma (mm), ovarian tumors, cancer, renal, genetic change, carcinoma lung, lung carcinoma
Clinical Study IdentifierNCT03702309
SponsorUniversity Health Network, Toronto
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with either histological confirmation of a solid tumor or hematological malignancy, OR patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration)
Patient must be 18 years old
All patients must have signed and dated an informed consent form for this LIBERATE study
If patients are being co-consented for a separate primary research study listed in Appendix I, they must fulfill the eligibility criteria for that separate primary research study. If there is a discrepancy in the eligibility criteria between protocols, the separate primary research study's criteria take precedence

Exclusion Criteria

None
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note